cardiorentis.com
Startseite - Cardiorentis AGCardiorentis
http://www.cardiorentis.com/
Cardiorentis
http://www.cardiorentis.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Saturday
LOAD TIME
1.5 seconds
16x16
Johannes Holzmeister
Johannes Holzmeister
Kaser●●●●●. 77A
Zu●●ch , -, 8004
CH
View this contact
Johannes Holzmeister
Johannes Holzmeister
Kaser●●●●●. 77A
Zu●●ch , -, 8004
CH
View this contact
Swisscom Fixnet AG
Hostcenter Hostcenter
Hardtu●●●●●●asse 3
Zu●●ch , ZH, 8037
CH
View this contact
BUY YOUR DOMAIN
14
YEARS
1
MONTHS
23
DAYS
MELBOURNE IT, LTD. D/B/A INTERNET NAMES WORLDWIDE
WHOIS : whois.melbourneit.com
REFERRED : http://www.melbourneit.com
PAGES IN
THIS WEBSITE
14
SSL
EXTERNAL LINKS
2
SITE IP
217.26.52.196
LOAD TIME
1.476 sec
SCORE
6.2
Startseite - Cardiorentis AG | cardiorentis.com Reviews
https://cardiorentis.com
Cardiorentis
cardiorentis.com
SIRIUS I and II - Cardiorentis AG
http://www.cardiorentis.com/de/rd/sirius-i-and-ii.php
Caution - Investigational Drug; Limited by United States Law to Investigational use only. Caution - Investigational Drug; Limited by United States Law to Investigational use only. SIRIUS I and II. SIRIUS I and II. SIRIUS I (Phase IIa). SIRIUS I was a randomised, double-blind, ascending-dose study. Twenty four patients with AHF received 24 hour IV infusion of placebo or ularitide at 7.5, 15, or 30 ng/kg/min in addition to standard therapy. View the SIRIUS I research paper. SIRIUS II (Phase IIb). The SIRIU...
TRUE- AHF Phase III clinical trial - Cardiorentis AG
http://www.cardiorentis.com/de/rd/true-ahf.php
Caution - Investigational Drug; Limited by United States Law to Investigational use only. Caution - Investigational Drug; Limited by United States Law to Investigational use only. SIRIUS I and II. TRUE- AHF Phase III clinical trial. Fficacy and safety in patients with A. The goal of TRUE-AHF will be to evaluate the efficacy and safety of ularitide on clinical status and mortality outcomes of patients with AHF. First co-primary efficacy endpoint. Moderately or markedly improved at all three time points (a...
Team - Cardiorentis AG
http://www.cardiorentis.com/de/about/team.php
Caution - Investigational Drug; Limited by United States Law to Investigational use only. Caution - Investigational Drug; Limited by United States Law to Investigational use only. SIRIUS I and II. Johannes Holzmeister, MD. Chairman and Chief Executive Officer (CEO). Executive Vice President and Chief Financial Officer (CFO). Stefan Mazgareanu, PhD. Senior Vice President and Chief Operating Officer (COO). Markus Meyer, MD. Senior Vice President and Chief Medical Officer (CMO). Hanns-Eberhard Erle, PhD.
Corporate Background - Cardiorentis AG
http://www.cardiorentis.com/de/about/index.php?navid=517552517552
Caution - Investigational Drug; Limited by United States Law to Investigational use only. Caution - Investigational Drug; Limited by United States Law to Investigational use only. SIRIUS I and II. Cardiorentis AG is a privately owned biopharmaceutical company designed for the new world of drug development. Focused, fast moving and flexible, with patients at its heart, Cardiorentis AG is committed to bringing novel therapies to the treatment of heart failure and related cardiovascular diseases.
Disclaimer - Cardiorentis AG
http://www.cardiorentis.com/de/disclaimer/index.php
Caution - Investigational Drug; Limited by United States Law to Investigational use only. Caution - Investigational Drug; Limited by United States Law to Investigational use only. SIRIUS I and II. Terms and Conditions of Use. Reservation of right of modification. The author expressly reserves the right to modify, supplement or delete parts of this web site or the entire content without separate notice and to discontinue publication thereof either temporarily or permanently. Information on data protection.
TOTAL PAGES IN THIS WEBSITE
14
Chelation | Oral EDTA Chelation Therapy | Cardio Renew
All Packages and Prices. Complete 6 Week Chelation/Cholesterol Pack. 6 Week Chelation Pack. 6 Week Cholesterol or 6 Month Maintenance Pack. 6 Week Chelation Program. Complete Six Week Program Overview. How is Oral EDTA Effective? What is Krill Oil and How is it Effective? Oral vs. IV Chelation. Absorption: Pills vs. Liquids. High Blood Pressure / Hypertension. PAD (Peripheral Artery Disease). EDTA Chelation and Krill Oil Promote:. Cardio Renew Canada Products. Sharon H. B. I was diagnosed with PAD. Thank...
EDTA Chelation Therapy - International Distributors of Cardio Renew
Advanced Oral Chelation Therapy. This is the International site for Cardio Renew Chelation Therapy. For Orders Within Europe Please Click Here. Have you experienced any of the following symptoms. Higher than normal blood pressure. Leg pain on walking a short distance. Easily out of breath and lacking energy. Cold feet or hands. A lot of the above is generally put down to aging but more than likely you are suffering from restricted blood flow caused by artery blockage. EDTA has been shown to remove minera...
cardio renew sa
6 Weeks System Pack. All Packages and Prices. 6 Week System pack. Vitamin C and E Soft-Gels. 6 week system cleanse. How is Oral EDTA Effective? Absorption Pills vs.Liquids. Required Disclaimer: The statements made about our product have not been evaluated by the Food and Drug Administration. The products and information on this site are not intended to treat, cure or prevent any condition or disease. Oral Liquid EDTA System Cleanse. The System Approach to Cardio Health. Listen To Your Body. To all critic...
cardiorent.de steht zum Verkauf
Diese Domain steht zum Verkauf! Die Domain cardiorent.de wird vom Inhaber im Marktplatz angeboten. Sie können diese Domain jetzt erwerben! Der Inhaber dieser Domain parkt diese beim Domain-Parking-Programm.
Startseite - Cardiorentis AG
Caution - Investigational Drug; Limited by United States Law to Investigational use only. Caution - Investigational Drug; Limited by United States Law to Investigational use only. SIRIUS I and II. Cardiorentis is a privately owned biopharmaceutical company designed for the new world of drug development. AHF can be defined as the sudden or gradual onset of the signs or symptoms of heart failure resulting in a need for urgent therapy or hospitalisation. Welcome to Cardiorentis AG. SIRIUS I and II.
Startseite - Cardiorentis AG
Caution - Investigational Drug; Limited by United States Law to Investigational use only. Caution - Investigational Drug; Limited by United States Law to Investigational use only. SIRIUS I and II. Cardiorentis is a privately owned biopharmaceutical company designed for the new world of drug development. AHF can be defined as the sudden or gradual onset of the signs or symptoms of heart failure resulting in a need for urgent therapy or hospitalisation. Welcome to Cardiorentis AG. SIRIUS I and II.
Startseite - Cardiorentis AG
Caution - Investigational Drug; Limited by United States Law to Investigational use only. Caution - Investigational Drug; Limited by United States Law to Investigational use only. SIRIUS I and II. Cardiorentis is a privately owned biopharmaceutical company designed for the new world of drug development. AHF can be defined as the sudden or gradual onset of the signs or symptoms of heart failure resulting in a need for urgent therapy or hospitalisation. Welcome to Cardiorentis AG. SIRIUS I and II.
Startseite - Cardiorentis AG
Caution - Investigational Drug; Limited by United States Law to Investigational use only. Caution - Investigational Drug; Limited by United States Law to Investigational use only. SIRIUS I and II. Cardiorentis is a privately owned biopharmaceutical company designed for the new world of drug development. AHF can be defined as the sudden or gradual onset of the signs or symptoms of heart failure resulting in a need for urgent therapy or hospitalisation. Welcome to Cardiorentis AG. SIRIUS I and II.
Startseite - Cardiorentis AG
Caution - Investigational Drug; Limited by United States Law to Investigational use only. Caution - Investigational Drug; Limited by United States Law to Investigational use only. SIRIUS I and II. Cardiorentis is a privately owned biopharmaceutical company designed for the new world of drug development. AHF can be defined as the sudden or gradual onset of the signs or symptoms of heart failure resulting in a need for urgent therapy or hospitalisation. Welcome to Cardiorentis AG. SIRIUS I and II.
Cardioreparation
Cardiovascular diseases have been identified as "public health enemy no. 1" by the World Health Organization. Cardiovascular diseases kill more people than any other single disease. The search for reliable preventive methods should be pursued. Prevention of heart failure (HF) and sudden death (SCD) requires. Repair - gene expression in HF. Safe pericardial access for epicardial leads and ablation. Repair - electrical instability, SCD. HUFA deficiency in HF. Blood EPA DHA Level. From plaque to sudden death.
Cardioreparation
Cardiovascular diseases have been identified as "public health enemy no. 1" by the World Health Organization. Cardiovascular diseases kill more people than any other single disease. The search for reliable preventive methods should be pursued. Prevention of heart failure (HF) and sudden death (SCD) requires. Repair - gene expression in HF. Safe pericardial access for epicardial leads and ablation. Repair - electrical instability, SCD. HUFA deficiency in HF. Blood EPA DHA Level. From plaque to sudden death.
